Accessibility Menu
Sino Biopharmaceutical logo

Sino Biopharmaceutical(OTC) SBMFF

Market Cap$13.15BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2010)+109%
5 Year-4%
1 Year-24%
1 Month+16%
$0.73
+0.00%
+0.00Today
Sino Biopharmaceutical last closing stock price
MetricPriceDate
Last closeUSD 0.732026-08-31
Sino Biopharmaceutical stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-1.6%USD 0.742026-08-21
1 month+15.92%USD 0.632026-07-13
3 month+17.88%USD 0.622026-05-28
Year to date-14.42%USD 0.852025-12-22
1 year-24.05%USD 0.962025-08-13
3 year+110.68%USD 0.352023-08-29
5 year-4.24%USD 0.762021-09-01
Since inception+108.75%USD 0.352010-03-11

Sino Biopharmaceutical Financials at a Glance

Market Cap

$13.15BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CN¥33.70B

Net Income (TTM)

CN¥2.39B

EPS (TTM)

$0.02

P/E Ratio

37.67

Dividend

$0.02

Beta (Volatility)

0.10 (Low)

Price

$0.73

Volume

304

Open

$0.73

Previous Close

$0.73

Daily Range

$0.73 - $0.73

52-Week Range

$0.59 - $1.24

Estimated Earnings Date

Apr 1, 2027

SBMFF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Sino Biopharmaceutical

Sino Biopharmaceutical Limited is a prominent investment holding entity and a research and development-focused pharmaceutical conglomerate based in the People's Republic of China. The company operates across three main divisions: Modernised Chinese Medicines, Chemical Medicines, and various investment initiatives.

Products and Services
  • Offers a wide range of oncology medications and cardio-cerebral vascular drugs
  • Produces treatments for hepatitis and orthopedic medicines
  • Engages in healthcare services, including hospital operations and medical consultancy
Growth Outlook
  • Revenue of CNY 7.13 billion in Q4 2025 indicates strong market demand
  • Net income of CNY 1.69 billion in Q2 2025 shows profitability potential
  • Continued investment in R&D supports long-term growth strategies
Financial Highlights
  • Trailing twelve months (TTM) revenue of CNY 30.5 billion reflects consistent performance
  • Gross profit margin of 82.07% demonstrates strong operational efficiency
  • Dividend yield of 1.79% offers attractive returns for investors
Sino Biopharmaceutical Limited has established itself as a key player in the pharmaceutical industry, particularly within China. The company's diverse product portfolio and commitment to research and development position it well for future growth. Recent financial performance highlights, including significant revenue and profitability, underscore the company's operational strength and market potential. Investors may find the company's focus on innovation and expansion in various therapeutic areas appealing as it navigates the evolving healthcare landscape.
AI Generated • Aug 22, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

21,435

CEO

S Y Tse

Website

www.sinobiopharm.com

Headquarters

Hong Kong, HK

SBMFF Financials

Key Financial Metrics (TTM)

Gross Margin

82.43%

Operating Margin

29.76%

Net Income Margin

7.09%

Return on Equity

7.56%

Return on Capital

14.19%

Return on Assets

2.87%

Earnings Yield

2.65%

Dividend Yield

2.07%

Payout Ratio

62.89%

Stock Overview

Market Cap

$13.15BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

17.81B

Volume

304

Avg. Volume

685.406

Financials (TTM)

Gross Profit

CN¥27.78B

Operating Income

CN¥10.03B

EBITDA

CN¥10.41B

Operating Cash Flow

CN¥6.13B

Capital Expenditure

-CN¥967.92M

Free Cash Flow

CN¥5.16B

Cash & ST Invst.

CN¥27.58B

Total Debt

CN¥17.17B

Sino Biopharmaceutical Performance Analysis

Sino Biopharmaceutical annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31CNY 3,865,053,398-7.2%
20232023-12-31CNY 3,697,855,080-4.3%
20242024-12-31CNY 4,010,961,6138.5%
20252025-12-31CNY 4,428,562,01010.4%
Sino Biopharmaceutical sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-18.9%
Q42025-12-31N/A
Q12026-03-3136.4%
Q22026-06-30N/A
Sino Biopharmaceutical annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31CNY 0.02-84.2%
20232023-12-31CNY 0.02-1.1%
20242024-12-31CNY 0.01-23.6%
20252025-12-31CNY 0.0233.1%
Sino Biopharmaceutical sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-130.9%
Q42025-12-31N/A
Q12026-03-31427.9%
Q22026-06-30N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

CN¥9.72B

+10.6%

Gross Profit

CN¥8.07B

+11.4%

Gross Margin

83.05%

N/A

Market Cap

$13.15BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$613.68K

N/A

Employees

21,435

N/A

Net Income

CN¥1.72B

+1.4%

EBITDA

CN¥3.55B

+80.1%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

CN¥27.58B

+39.1%

Total Debt

CN¥17.17B

+43.6%

Accounts Receivable

CN¥10.68B

+28.8%

Inventory

CN¥1.97B

-6.4%

Long Term Debt

CN¥8.49B

+175.4%

Short Term Debt

CN¥8.68B

-2.2%

Return on Assets

2.87%

N/A

Return on Invested Capital

17.85%

N/A

Free Cash Flow

CN¥0.00

-100.0%

Operating Cash Flow

CN¥0.00

-100.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
KRTXKaruna Therapeutics, Inc.
$329.83+0.03%
URGNUroGen Pharma Ltd.
$44.09-1.76%
IVAInventiva S.A.
$4.78-1.24%
ORMPOramed Pharmaceuticals Inc.
$5.01+1.62%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.15-0.12%
NVDANvidia
$230.36+0.01%
PATHUiPath
$15.19-0.17%
INTCIntel
$95.80+0.05%

Questions About SBMFF

What is the current price of Sino Biopharmaceutical?

Sino Biopharmaceutical is trading at $0.73 per share.

What is the 52-week range for Sino Biopharmaceutical?

Over the past 52 weeks, Sino Biopharmaceutical has traded between $0.59 and $1.24.

How much debt does Sino Biopharmaceutical have?

As of the most recent reporting period, Sino Biopharmaceutical reported total debt of CN¥2.30B.

How much cash does Sino Biopharmaceutical have on hand?

Sino Biopharmaceutical reported CN¥1.06B in cash and cash equivalents in its most recent financial results.

What is Sino Biopharmaceutical’s dividend yield?

Sino Biopharmaceutical currently has a dividend yield of 2.07%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services